PhRMA promises not to gouge on the (potential) coronavirus vaccine
The president of drug industry trade group PhRMA said yesterday that his industry is “deeply committed to ensuring affordable access” to coronavirus vaccines, but he stopped far short of laying out concrete steps drug makers would take to live up to that commitment.
“If you look at the context of other pandemics and other vaccines that have been developed, price has not been an issue,” PhRMA President Steve Ubl said at a briefing with reporters in Washington.
The remarks came during a whirlwind week on Capitol Hill, in which Democrats pushed to include language in a coronavirus emergency funding bill that would restrict how much drug makers could charge for these products. That bill, which the House passed yesterday and which the Senate is expected to vote on later this week, includes some restrictions on coronavirus vaccine pricing but stops short of imposing the types of top-down price controls opposed by drug makers.
“If you look at the context of other pandemics and other vaccines that have been developed, price has not been an issue,” PhRMA President Steve Ubl said at a briefing with reporters in Washington.
The remarks came during a whirlwind week on Capitol Hill, in which Democrats pushed to include language in a coronavirus emergency funding bill that would restrict how much drug makers could charge for these products. That bill, which the House passed yesterday and which the Senate is expected to vote on later this week, includes some restrictions on coronavirus vaccine pricing but stops short of imposing the types of top-down price controls opposed by drug makers.
.png)
No hay comentarios:
Publicar un comentario